Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 5, Issue 13
July 13 2021
Issue Cover

Table of Contents

EXCEPTIONAL CASE REPORTS

Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia
Suradej Hongeng,Usanarat Anurathapan,Duantida Songdej,Angsana Phuphuakrat,Kesinee Jongrak,Geoffrey Parsons,Briana Deary,Melissa Bonner,Gabor Veres,Mohammed Asmal
View Articletitled, Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination
Clinical Trials & Observations
Andrew Jay Portuguese,Cassandra Sunga,Rebecca Kruse-Jarres,Terry Gernsheimer,Janis Abkowitz
View Articletitled, Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

CLINICAL TRIALS AND OBSERVATIONS

Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
Clinical Trials & Observations
Lana Mucalo,Amanda M. Brandow,Mahua Dasgupta,Sadie F. Mason,Pippa M. Simpson,Ashima Singh,Bradley W. Taylor,Katherine J. Woods,Fouza I. Yusuf,Julie A. Panepinto
View Articletitled, Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
Supplemental data
Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B
Clinical Trials & Observations
Beatrice Nolan,Anna Klukowska,Amy Shapiro,Antoine Rauch,Michael Recht,Margaret Ragni,Julie Curtin,Sriya Gunawardena,Sutirtha Mukhopadhyay,Deepthi Jayawardene,Bent Winding,Kathelijn Fischer,Raina Liesner
View Articletitled, Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Clinical Trials & Observations
Alison R. Walker,Guido Marcucci,Jun Yin,William Blum,Wendy Stock,Jessica Kohlschmidt,Krzysztof Mrózek,Andrew J. Carroll,Ann-Kathrin Eisfeld,Eunice S. Wang,Sawyer Jacobson,Jonathan E. Kolitz,Mohan Thakuri,Grerk Sutamtewagul,Ravi Vij,Robert K. Stuart,John C. Byrd,Clara D. Bloomfield,Richard M. Stone,Richard A. Larson
View Articletitled, Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages
Serine Avagyan,Margaret C. Weber,Sai Ma,Meera Prasad,William P. Mannherz,Song Yang,Jason D. Buenrostro,Leonard I. Zon
View Articletitled, Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages
Supplemental data
Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish
Emanuele Gioacchino,Cansu Koyunlar,Joke Zink,Hans de Looper,Madelon de Jong,Tomasz Dobrzycki,Christopher B. Mahony,Remco Hoogenboezem,Dennis Bosch,Paulina M. H. van Strien,Martin E. van Royen,Pim J. French,Eric Bindels,Kirsten J. Gussinklo,Rui Monteiro,Ivo P. Touw,Emma de Pater
View Articletitled, Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish
Supplemental data

LYMPHOID NEOPLASIA

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Clinical Trials & Observations
Nora Liebers,Johannes Duell,Donnacha Fitzgerald,Andrea Kerkhoff,Daniel Noerenberg,Eva Kaebisch,Fabian Acker,Stephan Fuhrmann,Corinna Leng,Manfred Welslau,Jens Chemnitz,Jan-Moritz Middeke,Thomas Weber,Udo Holtick,Ralf Trappe,Roald Pfannes,Ruediger Liersch,Christian Spoer,Stefan Fuxius,Niklas Gebauer,Léandra Caillé,Thomas Geer,Christian Koenecke,Ulrich Keller,Rainer Claus,Dimitrios Mougiakakos,Stephanie Mayer,Andreas Huettmann,Christiane Pott,Arne Trummer,Gerald Wulf,Uta Brunnberg,Lars Bullinger,Georg Hess,Carsten Mueller-Tidow,Bertram Glass,Georg Lenz,Peter Dreger,Sascha Dietrich
View Articletitled, Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Supplemental data
Search for AL amyloidosis risk factors using Mendelian randomization
Charlie N. Saunders,Subhayan Chattopadhyay,Stefanie Huhn,Niels Weinhold,Per Hoffmann,Markus M. Nöthen,Karl-Heinz Jöckel,Börge Schmidt,Stefano Landi,Hartmut Goldschmidt,Paolo Milani,Giampaolo Merlini,Dorota Rowcieno,Philip Hawkins,Ute Hegenbart,Giovanni Palladini,Ashutosh Wechalekar,Stefan O. Schönland,Asta Försti,Richard Houlston,Kari Hemminki
View Articletitled, Search for AL amyloidosis risk factors using Mendelian randomization
Supplemental data
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
Clinical Trials & Observations
Marcella Kaddoura,David Dingli,Francis K. Buadi,Martha Q. Lacy,Morie A. Gertz,Angela Dispenzieri,Prashant Kapoor,Lisa Hwa,Amie Fonder,Miriam Hobbs,Suzanne Hayman,John Lust,Nelson Leung,Ronald S. Go,Yi Lin,Wilson Gonsalves,Taxiarchis Kourelis,Rahma Warsame,Robert A. Kyle,Stephen M. Broski,Vincent Rajkumar,Shaji Kumar
View Articletitled, Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia
Stavroula Ntoufa,Marina Gerousi,Stamatia Laidou,Fotis Psomopoulos,Georgios Tsiolas,Theodoros Moysiadis,Nikos Papakonstantinou,Larry Mansouri,Achilles Anagnostopoulos,Niki Stavrogianni,Sarka Pospisilova,Karla Plevova,Antonios M. Makris,Richard Rosenquist,Kostas Stamatopoulos
View Articletitled, <em>RPS15</em> mutations rewire RNA translation in chronic lymphocytic leukemia
Supplemental data

THROMBOSIS AND HEMOSTASIS

A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C)
Saravanan Subramaniam,Yamini Ogoti,Irene Hernandez,Mark Zogg,Fady Botros,Robert Burns,Jacob T. DeRousse,Chris Dockendorff,Nigel Mackman,Silvio Antoniak,Craig Fletcher,Hartmut Weiler
View Articletitled, A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C)
Supplemental data

TRANSPLANTATION

A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention
Clinical Trials & Observations
Lia Perez,Hugo Fernandez,Mohamed Kharfan-Dabaja,Farhad Khimani,Brian Betts,Asmita Mishra,Ernesto Ayala,Frederick L. Locke,Leonel Ochoa-Bayona,Michael Nieder,Joseph Pidala,Alex Achille,John Powers,Eva Sahakian,Ram Thapa,Xuefeng Wang,Claudio Anasetti
View Articletitled, A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention

ERRATA

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
View Articletitled, Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. <em>Blood Adv.</em> 2020;4(9):1965-1973.
Zhou Z, Nath R, Cerny J, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
View Articletitled, Zhou Z, Nath R, Cerny J, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <em>Blood Adv</em>. 2020;4(13):3180-3190.
Qi S, Milgrom S, Dabaja B, et al. Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Adv. 2020;4(9):2064-2072.
View Articletitled, Qi S, Milgrom S, Dabaja B, et al. Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. <em>Blood Adv.</em> 2020;4(9):2064-2072.
  • Cover Image

    Cover Image

    issue cover

    Poly(I:C) and thrombin augment cell surface tissue factor expression on human endothelial cells (EA.hy926 cells). Green indicates tissue factor, red indicates thrombomodulin, and blue indicates nuclei. See the article by Subramaniam et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals